Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Remedy Pharmaceuticals, a leader in stroke drug development, today announced that the U.S. Patent and Trademark Office (USPTO) has allowed two additional patents covering its large hemispheric ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

Springbok Analytics ( a leader in AI-powered muscle analysis, today announced its role in MOVE Peds, the first large-scale clinical study focused on pediatric facioscapulohumeral muscular dystrophy ...

Kodiak Sciences Inc. , today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Though Jason Clarke and Jake Gyllenhaal lead an A-list cast in Everest, the real star of the 2015 movie is the mountain itself. Located in the Himalayas near the China-Nepal border, Mount Everest is ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral edema (n=8 vs. n=5), arthralgia ... 90% reduction in Bullous Pemphigoid Disease Area Index ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...